Ultraviolet activation of PKD: Implications for skin cancer

Future Oncology

Volumn 7, Issue 4, 2011, Pages 485-487

  Bollag, Wendy B ^a,b   Bollag, Roni J ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

apoptosis; cell carcinoma; epidermis; keratinocyte; nonmelanoma skin cancer; src tyrosine kinase

Indexed keywords

ALEMTUZUMAB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; EPIDERMAL GROWTH FACTOR; HISTONE DEACETYLASE INHIBITOR; HYBRID PROTEIN; LIGAND; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR; PROTEASOME INHIBITOR; PROTEIN KINASE C; PROTEIN KINASE C MU; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RITUXIMAB; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; DNA DAMAGE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EPIDERMIS; GENE MUTATION; HUMAN; KERATINOCYTE; MULTIPLE MYELOMA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SKIN CANCER; SKIN CARCINOGENESIS; SKIN TUMOR; ULTRAVIOLET IRRADIATION;

ANTIBODIES, MONOCLONAL; APOPTOSIS; HUMANS; PROTEIN KINASE C; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TRPP CATION CHANNELS; ULTRAVIOLET RAYS;

EID: 79953722554     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.16     Document Type: Review

References (19)

1. Chari A, Mazumder A, Jagannath S: Proteasome inhibition and its therapeutic potential in multiple myeloma. Biologics 28, 273-287 (2010).
2. Knight ZA, Lin H, Shokat KM: Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10, 130-137 (2010)
3. An X, Tiwari AK, Sun Y, Ding P-R, Ashby CR Jr, Chen Z-S: Bcr-Abl tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk. Res. 34, 1255-1268 (2010).
4. Guha S, Tanasanvimon S, Sinnett-Smith J, Rozengurt E: Role of protein kinase D signaling in pancreatic cancer. Biochem. Pharmacol. 80, 1946-1954 (2010).
5. Lavalle CR, George KM, Sharlow ER, Lazo JS, Wipf P, Wang QJ: Protein kinase D as a potential new target for cancer therapy Biochim. Biophys. Acta 1806, 183-192 (2010).
6. Sinnett-Smith J, Zhukova E, Hsieh N, Jiang X, Rozengurt E: Protein kinase D potentiates DNA synthesis induced by Gq-coupled r eceptors by increasing the duration of ERK signaling in Swiss 3T3 cells. J. Biol. Chem 279, 16883-16893 (2004). (Pubitemid 38509391)
7. Harikumar KB, Kunnumakkara AB, Ochi N et al.: A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol. Cancer Ther. 9, 1136-1146 (2010).
8. Syed V, Mal P, Du C, Balaji KC: β-catenin mediates alteration in cell proliferation, motilit y and invasion of prostate cancer cells by differential expression of E-cadherin and protein kinase D1. J. Cell. Biochem. 104, 82-95 (2008).
9. Sharlow ER, Giridhar KV, La Valle CR et al.: Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone. J. Biol. Chem. 283, 33516-33526 (2008).
10. Chen J, Deng F, Singh SV, Wang QJ: Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKCepsilon/PKD3 pathway downstream of Akt and ERK 1/2. Cancer Res. 68, 3844-3853 (2008).
11. Bollag WB, Dodd ME, Shapiro BA: Protein kinase D and keratinocyte proliferation. Drug News Persp. 17, 117-126 (2004). (Pubitemid 38568409)
12. Dodd ME, Ristich VL, Ray S, Lober RM, Bollag WB: Regulation of protein kinase D during differentiation and proliferation of primary mouse keratinocytes. J. Invest. De rmatol. 125, 294-306 (2005). (Pubitemid 41648163)
13. Arun S, Xie D, Dodd ME, Zhong X, Bollag WB: The potential use of protein kinase D inhibitors for prevention/treatment of epidermal tumors. J. Dermatol. Sci. 60, 29-39 (2010).
14. Jadali A, Ghazizadeh S: Protein kinase D is implicated in the reversible commitment to differentiation in primary cultures of mouse keratinocytes. J. Biol. Chem. 285, 23387-23397 (2010).
15. Ivanova P, Atanasova G, Poumay Y, Mitev V: Knockdown of PKD1 in normal human epidermal keratinocytes increases mRNA expression of keratin 10 and involucrin: early markers of keratinocyte differentiation. Arch. Dermatol. Res. 300, 139-145 (2008).
16. Ristich VL, Bowman PH, Dodd ME, Bollag WB: Protein kinase D distribution in normal human epidermis, basal cell carcinoma and psoriasis. Br. J. Dermatol. 154, 586-593 (2006). (Pubitemid 43374080)
17. Chen J, Ruczinski I, Jorgensen TJ et al.: Nonmelanoma skin cancer and risk for subsequent malignancy. J. Natl Cancer Inst. 100, 1215-1222 (2008).
18. Arun SN, Kaddour-Djebbar I, Shapiro BA, Bollag WB: Ultraviolet B irradiation and activation of protein kinase D in primary mouse epidermal keratinocytes. Oncogene DOI: 10.1038/onc.2010.540 (2010) (Epub ahead of print).
19. Lavalle CR, Bravo-Altamirano K, Giridhar KV et al.: Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility. BMC Chem. Biol. 10, 5 (2010).